Invesco Ltd. Sells 296,924 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Invesco Ltd. cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 25.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 864,249 shares of the biopharmaceutical company's stock after selling 296,924 shares during the quarter. Invesco Ltd. owned approximately 0.79% of Regeneron Pharmaceuticals worth $615,631,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of the company. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $28,000. Avalon Trust Co acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $36,000. Crowley Wealth Management Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $36,000. Finally, Private Wealth Management Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 260.0% during the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after buying an additional 39 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 4th. Truist Financial cut their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating for the company in a research report on Wednesday, January 8th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their target price for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 5th. Finally, Citigroup reduced their price objective on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $966.88.

Remove Ads

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $7.79 during trading on Friday, reaching $554.18. The company's stock had a trading volume of 1,170,894 shares, compared to its average volume of 707,716. The stock has a 50-day moving average price of $659.94 and a two-hundred day moving average price of $753.23. The stock has a market capitalization of $60.59 billion, a P/E ratio of 14.48, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a one year low of $525.99 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the previous year, the firm posted $11.86 earnings per share. The company's revenue was up 10.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.